Alignment Healthcare vs Humana
ALHC and HUM side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALHC and HUM compare
Humana is the larger company, worth 33 times as much as Alignment Healthcare ($53.2B against $1.6B).
On earnings, Humana is cheaper: it trades at 41.8× trailing earnings, against 69.3× for Alignment Healthcare.
Alignment Healthcare grew revenue faster over the last twelve months (35.9% versus 18.3% for Humana).
Humana keeps more of each dollar of sales as profit, with a net margin of 0.88% compared with 0.59% at Alignment Healthcare.
Humana pays a dividend yielding 0.60%; Alignment Healthcare does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALHC | HUM |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $53.2B |
| Share price | $7.62 | $443.34 |
| Change, 1 year | −53.9% | 87.0% |
| Change, 5 years | −56.1% | 3.5% |
| Beta (5Y) | 0.63 | 1.10 |
| Employees | 1,849 | 67K |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 1 | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 69.3× | 41.8× (better) |
| P/S | 0.3× (better) | 0.4× |
| P/B | 5.8× | 2.8× (better) |
| EV/EBITDA | 15.6× | 13.0× (better) |
| P/FCF | 20.7× (better) | 27.3× |
| FCF yield | 4.8% (better) | 3.7% |
| Fair value | $4.97 | $297.30 |
| Margin of safety | −53.4% | −49.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 35.9% (better) | 18.3% |
| Revenue growth, 5Y average | 32.7% (better) | 10.9% |
| Net income growth (TTM) | – | −18.8% |
| EPS growth (TTM) | – | −18.8% |
| EPS growth, 5Y average | – | −17.2% |
| Profitability | ||
| Operating margin | 0.88% | 1.9% (better) |
| Net margin | 0.59% | 0.88% (better) |
| FCF margin | 1.6% (better) | 1.3% |
| Return on equity | 13.2% (better) | 6.8% |
| Return on invested capital | – | 23.4% |
| Financial health | ||
| Debt / equity | 1.17 | 0.74 (better) |
| Net debt / EBITDA | −5.57 | −2.86 |
| Interest coverage | 2.6× | 3.8× (better) |
| Current ratio | 1.71 | 1.74 (better) |
| Altman Z-score | 4.27 | 4.66 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.60% |
| Payout ratio | – | 33.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 7.8% |
| Buyback yield | – | 0.28% |
| Shareholder yield | 0.00% | 0.88% (better) |
| Ownership | ||
| Held by institutions | 106% | 98.6% |
| Held by insiders | 4.6% | 0.32% |
| Insider net buying, 12 months | −$517M | −$2.4M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 11.6% | 2.3% |
Go deeper
- ALHC stock overview
- ALHC income statement
- ALHC valuation and score
- HUM stock overview
- HUM income statement
- HUM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.